Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.33 |
| ▸ | PDE2A | O00408 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771012 | 0.92 | CACNA1B (0.36) | PDE2ACYP2C9MAPTCACNA1GCACNA1B | |
| SCHEMBL4943359 | 0.89 | CNR1 (0.34) | GAACYP2C9KDM4EMAPT | |
| SCHEMBL5489054 | 0.87 | LMNA (0.33) | LMNAPOLBGAAPDE2AKDM4E | |
| SCHEMBL3273514 | 0.84 | CNR1 (0.34) | CYP2C9KDM4EMAPTCRHR1 | |
| SCHEMBL4763543 | 0.79 | CACNA1B (0.35) | PDE2AMAPTCACNA1GCACNA1BCACNA1C | |
| SCHEMBL3930715 | 0.79 | GPR119 (0.35) | CYP2C9GPR119 | |
| SCHEMBL3281407 | 0.79 | CNR1 (0.33) | CYP2C9KDM4EMAPT | |
| SCHEMBL5489084 | 0.76 | IDO1 (0.34) | CYP2C9KDM4EMAPT | |
| SCHEMBL5492061 | 0.76 | ALDH1A1 (0.34) | GAACYP2C9KDM4EMAPT | |
| SCHEMBL3271971 | 0.76 | RXRA (0.33) | CYP2C9KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279474-B2 | Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) | GLAXO GROUP LIMITED (GB) | 2007-10-09 | — | — | US | disclosed |
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | GLAXO GROUP LIMITED (GB) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176400-A1 | Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) | CRH, CRHR1, CRHR2 | LMNA 4763/4885POLB 2581/4885GAA 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.